This is the authors' abstract. We don't add key points for this paper.
Calcium sulphate is an established carrier for localized drug delivery, but a means to non-invasively measure drug release, which would improve our understanding of localized delivery, remains an unmet need. We aim to quantitatively estimate the diffusion-controlled release of small-molecules loaded into a calcium sulphate carrier through gadobutrol-based contrast agent, which acts as a surrogate small-molecule. A central cylindrical core made of calcium sulphate, either alone or within a metal scaffold, is loaded with contrast agent that releases into agar. Multi-echo scans are acquired at multiple time-points over 4 weeks and processed into R2* and QSM maps. Mean R2*values are fit to a known drug delivery model, which are then compared to the decrease in core QSM. Fitting R2* measurements of calcium sulphate core while constraining constants to a drug release model results in a R 2 -value of 0.991, yielding a diffusion constant of 4.59x10 -11 m 2 /s. Incorporating the carrier within a metal scaffold results in a slower release. QSM shows the resulting loss of susceptibility in the non-metal core but is unreliable around metal. R2* characterizes gadobutrol release and QSM detects the resulting decrease in susceptibility. The addition of a porous metal scaffold slows the release of gadobutrol, as expected.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: